Attalla Consultants LLC — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$7,173	11
2019	Research	$155,151	29

Breakdown

Who paid Research payments · program years 2019–2020

Sunovion Pharmaceuticals Inc. $96,941 2 payments
Pfizer Inc. $41,980 32 payments
Shire North American Group Inc $18,605 5 payments
Takeda Pharmaceuticals U.S.A., Inc. $4,798 1 payment

Studies the money was for Research payments · program years 2019–2020

Pediatric Open-Label Extension Study $96,941 2 payments
A Phase 3 Multicenter Fourweek Randomized Doubleblind Placebocontrolled Parallelgroup Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder Current Or Most Recent Episode Manic $35,760 25 payments
Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficithyperactivity Disorder Adhd $13,197 3 payments
Efficacy and Safety of Shp465 at 6.25 MG in the Treatment of Attention-Deficithyperactivity Disorder Adhd in Children Aged 6-12 Years $5,408 2 payments
Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (Adhd) $4,798 1 payment
Sprites Sertraline Pediatric Registry for the Evaluation of Safety A Noninterventional Longitudinal Cohort Study to Evaluate the Effects of Longterm Sertraline Treatment in Children and Adolescents $4,680 5 payments
Pilot Outcome Study of the Incidence of the Safety Events of Interest Among Persons Prescribed Sertraline Using A Japanese Administrative Healthcare Claims Database $1,040 1 payment
Preliminary Be Study $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.